Lead Research Nurse
Julia joined the Emergency Department (ED) in 2008, having started off her nursing career at the Breast unit at the Western General Hospital. Working in the ED was a dream come true; each day brought opportunities to learn something new. It was an exciting and hectic place to work, staffed by highly energetic and spirited individuals. Through the laughs and, at times, the tears, she gained a wealth of knowledge and life-saving skills, and it was with mixed feelings that she embarked upon the next stage of her career, moving to the EMERGE team in 2012.
Emergency research nursing promised a change of scene and a new focus on the academic side of medical care. However, having accepted the job, she decided she had better brush up on her research skills! She duly enrolled on a course in Clinical Research at University, and graduated with a BSc in 2013. In order to retain a balance between the science and the practice, she also completed the Clinical Decision Making module a year later a year later, which she passed with merit.
After settling in to the EMERGE team, working across a number of studies and completing a heart failure audit, Julia became lead co-ordinator for LAVAS and CVLA. After completion of these studies she was asked to present the findings at the Royal College of Nursing International Conference of Research in Nottingham in April 2015. Currently, Julia is co-ordinating a phase one Randomised Open Label Exploratory, Safety and Tolerability Clinical Trial looking at a new drug (Calmangafodipir) in combination with Acetylcysteine to see if using these two drugs together is safe and if it is better at preventing damage to the liver than using Acetylcysteine only. For more information, see the POP study on our projects page.
Out of work, she’s on a maniacal mission to become the Bionic Woman, so far, no cigar.
Grahamslaw, J on behalf of EMERGE. How Research Active are you? Emergency Nurse RCNi. (2015) volume 23 Number 2 page 15
LAVAS and CVLA
• NHS Lothian R&D conference – March 2015.
• RCN International Conference of Research – April 2015.
• Royal College of Emergency Medicine – May 2015
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
Traumatic Brain Injury (TBI) is the leading cause of death and disabilities amongst young people worldwide. Many sufferers develop chronic physical and mental health problems and are unable to work or re-engage socially after their injuries. There are therefore significant health and socioeconomic consequences.
A study examining the Prevalence and Risk of Anterior Pituitary Dysfunction following Traumatic Brain Injury
In the Liver Unit at the Royal Infirmary of Edinburgh, we are involved in research to improve the treatment available for people with liver cirrhosis. Cirrhosis of the liver can make people vulnerable to other potentially serious complications including kidney problems.
The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.
A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose
Evaluating the kinetics of cardiac biomarkers after ST-segment Elevation myocardial infarction
This is a study looking at incidence and risk factors for poor ankle functional recovery, and the development and progression of post-traumatic ankle osteoarthritis after significant ankle ligament injury.
SALI study - Significant Ankle Ligament Injury
This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.
Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)
Determining whether an agreement between peripheral venous and arterial lactate exists in patients presenting to an Emergency Department with sepsis.
Lactate, Arterial and Venous Agreement in Sepsis
Determining the feasibility of a study investigating the agreement between capillary and peripheral venous lactate in the Emergency Department
Capillary and Venous Lactate Agreement
Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world
Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events
The Pharmacogenetics of Thiazide Induced Hyponatraemia
The Pharmacogenetics of Thiazide Induced Hyponatraemia
Evaluating the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients (CRLXA).
Evaluating Serelaxin in acute heart failure patients
To derive a biomarker to allow the identification of patients with confirmed sepsis, and risk stratify patients at risk of developing severe sepsis
Early Prediction of Severe Sepsis
To produce a predictive tool for HSV encephalitis by comparing those with and without the infection.
Understanding and improving the outcome in Encephalitis
16 Nov 2015 | Julia Grahamslaw
Julia Grahamslaw - Winner Elsie Inglis AwardRead more
26 May 2015 | Jen Simpson
Our very own Jen Simpson, takes us through the roller coaster ride that is 24 hours in the shoes of a Research Nurse.Read more